TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05735080: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Sponsor: Incyclix Bio · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,639,400

Rescue Site Savings

+$5,694,150

Unlock Full NCT05735080 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05735080 Rescue Dossier →